Serum Calprotectin – a NET Product – as a Biomarker of Disease Activity in Patients with Systemic Lupus Erythematosus: A Single-Center Case-Control Study from Poland

13 July 2022 : Clinical Research

Iwona Homa-Mlak^1ACDEF*, Marcin Mazurek^1BCEF, Aleksandra Majdan

^1DEF, Radosław Mlak^1ACDE, Maria Majdan

^2ADEF, Teresa Mełecka-Massalska^1ADEF

DOI: 10.12659/MSM.936534

Med Sci Monit 2022; 28:e936534

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Differences in calprotectin value depending on demographic and clinical factors in the study group.

Variable	Median	p
Male	3.10	0.7735
Female	3.11	0.7735

Age (years)		0.0562
<36.5	3.14
>36.5	3.06

Duration of the disease (years)		0.8611
<6	3.11
>6	3.10

SLEDAI		0.6907
Mild and moderate	3.11
Severe	3.41

SLEDAI		0.2030
Mild	3.11
Moderate and severe	3.39

Calprotectin [ng/ml]		0.0013^*
Study group	3.11
Control group	2.45
^* Statistically significant results. SLEDAI – Systemic Lupus Erythematosus Disease Activity Index.

Back to the Article